22 peptides tracked

Australia's
Independent
Peptide Register

No vendors. No affiliates. Just data.

Fig. 01
Regulatory Status · April 2026
Retatrutide
2
GHK-Cu
10
Semaglutide
12
Tirzepatide
8
BPC-157
18
CJC-1295
15
Provider count · Australian prescription access · n=22 peptides
22
Peptides tracked
40
Prescription providers
37
Observed suppliers
1
Prohibited (S9)
01Intelligence

Peptide Status

TGA scheduling, enforcement trends, and access pathways for each peptide. Updated April 2026.

Editorial position: We recommend accessing peptides through an AHPRA-registered medical practitioner and TGA-licensed compounding pharmacy. This ensures clinical oversight, pharmaceutical-grade compounding, and legal compliance.

Retatrutide
Triple Agonist (GLP-1/GIP/Glucagon)
Under Review
ScheduleS4
EnforcementMonitoring
RiskMedium Risk
Providers2
GHK-Cu
Copper Peptide
Prescription Only
ScheduleS4
EnforcementStable
RiskLow Risk
Providers10
Semaglutide
GLP-1 Agonist
Prescription Only
ScheduleS4
EnforcementTightening
RiskLow Risk
Providers12
Tirzepatide
GLP-1/GIP Agonist
Prescription Only
ScheduleS4
EnforcementTightening
RiskMedium Risk
Providers8
BPC-157
Tissue Repair
Prescription Only
ScheduleS4
EnforcementStable
RiskLow Risk
Providers18
CJC-1295
Growth Hormone Secretagogue
Prescription Only
ScheduleS4
EnforcementStable
RiskLow Risk
Providers15
Ipamorelin
Growth Hormone Secretagogue
Prescription Only
ScheduleS4
EnforcementStable
RiskLow Risk
Providers15
TB-500
Tissue Repair
Prescription Only
ScheduleS4
EnforcementMonitoring
RiskMedium Risk
Providers8
Melanotan II
Melanocortin Agonist
Prohibited
ScheduleS9
EnforcementTightening
RiskHigh Risk
Providers0
PT-141 (Bremelanotide)
Melanocortin Agonist
Prescription Only
ScheduleS4
EnforcementStable
RiskMedium Risk
Providers5
MOTS-c
Mitochondrial Peptide
Prescription Only
ScheduleS4
EnforcementMonitoring
RiskMedium Risk
Providers4
Thymosin Alpha-1
Immune Modulator
Prescription Only
ScheduleS4
EnforcementStable
RiskLow Risk
Providers6
KPV
Anti-inflammatory Peptide
Prescription Only
ScheduleS4
EnforcementStable
RiskLow Risk
Providers3
Epithalon
Telomerase Activator
Available
ScheduleUnscheduled
EnforcementMonitoring
RiskMedium Risk
Providers2
Gonadorelin
Hormonal Support
Prescription Only
ScheduleS4
EnforcementStable
RiskLow Risk
Providers12
Dihexa
Cognitive Enhancement
Prescription Only
ScheduleS4
EnforcementMonitoring
RiskMedium Risk
Providers3
02News

Regulatory Feed

Latest scheduling changes, enforcement actions, and market developments across all tracked peptides.

HeadlineSourceDate
Injectable peptides are the new anti-ageing trend - but what evidence do we have?MK-677 (Ibutamoren)
UNSW1 Apr 2026
2026 Prohibited ListTB-500
Sport Integrity Australia1 Jan 2026
Retatrutide delivered weight loss with relief from osteoarthritis pain in first Phase 3 trialRetatrutide
Eli Lilly11 Dec 2025
WHO issues global guideline on the use of GLP-1 medicines in treating obesitySemaglutide
WHO1 Dec 2025
FDA approves first treatment for Barth syndromeSS-31 (Elamipretide)
FDA1 June 2025
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activityEpithalon
PubMed1 June 2025
Epitalon increases telomere length - full textEpithalon
PMC1 June 2025
Tirzepatide as Compared with Semaglutide for Obesity (SURMOUNT-5)Tirzepatide
NEJM11 May 2025
Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospectiveGHK-Cu
PubMed1 Feb 2025
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiencyTirzepatide
Nature Medicine1 Jan 2025
Update: Ozempic supply to remain limited in 2025Semaglutide
TGA1 Jan 2025
Wegovy recommended for PBS listingSemaglutide
RACGP1 Jan 2025
Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP)Semaglutide
The Lancet1 Jan 2025
Obesity drug leads to 25% weight loss in a third of patientsTirzepatide
Medical Republic1 Jan 2025
The Potential of Semax for Correcting Pathological Impairments in Alzheimer's DiseaseSemax
PMC1 Jan 2025
MAHA peptides wave erodes Australian healthcareMK-677 (Ibutamoren)
Medical Republic1 Jan 2025
Advertising therapeutic goods on social media - TGA guidanceBPC-157
TGA1 Jan 2025
Thymalfasin (Thymosin Alpha 1) as an Enhancer of ImmunotherapyThymosin Alpha-1
ClinicalTrials.gov1 Jan 2025
FDA approves first medication for obstructive sleep apnea (Zepbound/tirzepatide)Tirzepatide
FDA.gov20 Dec 2024
Semaglutide for cardiovascular risk reduction in people with obesity (new indication)Semaglutide
Australian Prescriber1 Dec 2024
Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.